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Summary 
Identification of the localization of human T lymphotrophic virus type I (HTLV-I) proviral DNA 
in the central nervous system (CNS) is crucial to the understanding of the pathogenesis of HTLV- 
I-associated myelopathy (HAM)/tropical spastic paraparesis (TSP) pathogenesis.  We have developed 
a sensitive detection method, called two-step polymerase chain reaction (PCR) in situ hybridization, 
which enabled us to detect the HTLV-I proviral DNA in paraffin-embedded spinal cord tissue 
sections from HAM/TSP patients. HTLV-I proviral DNA was detected only in the nucleus of 
lymphocytes that had infiltrated into the spinal cord. However, no proviral DNA was amplified 
in any neuronal cells, including neurons and glial cells. This indicates that the demyelination 
of the spinal cord by HTLV-I as a result of viral infection of oligodendrocytes or neuronal cells 
is unlikely. The T cell receptor V/3 gene sequence from lymphocytes in the spinal cord lesions 
taken from the same HAM/TSP autopsy cases revealed unique and restricted CDR3  motifs, 
CASSLXG(G) (one-letter amino acid. X is any amino acid), CASSPT(G), and CASSGRL which 
are similar to those described in T  cells from brain lesions of multiple sclerosis  (MS) and in 
a rat T cell clone derived from experimental allergic encephalomyelitis (EAE) lesions. The present 
results suggest that T  cells containing restricted V3 CDK3  motifs, which are also found in 
MS and EAE, become activated upon HTLV-I infection and infiltrate into the spinal cord lesions 
of HAM/TSP patients. 
H 
'uman  T  lymphotrophic  virus  type  I  (HTLV-I) ~ is 
. known to be a causative agent of adult T cell leukemia 
(ATL)  (1,  2)  and  HTLV-I-associated myelopathy/tropical 
spastic paraparesis (HAM/TSP) (3, 4). HAM/TSP is a chronic 
neurological disease characterized by spastic paraparesis  and 
urinary dysfunction. HTLV-I is endemic in the Kyushu area 
of Japan, the Caribbean, Africa, and the South Pacific area. 
This disease has some clinical aspects similar to those of mul- 
tiple sclerosis (MS) for which the etiology is still unknown. 
1 Abbreviations used in this paper: ATL, adult T cell leukemia;  CNS, central 
nervous system;  EAE, experimental  allergic  encephalomyelitis;  HAM/TSP, 
HTLV-I-associated  myelopathy/tropical  spastic  paraparesis;  HTLV-I, human 
T Iymphotrophic  virus type I; MBP, myelin  basic protein. 
Less than 1% of HTLV-1 carriers develop clinical disease. This 
suggests that individual differences in genetic predisposition 
may be related to the pathogenesis of HAM/TSP. The patho- 
genesis of HAM/TSP is still controversial. There are several 
hypotheses: (a) a slow viral infection of HTLV-1 which might 
cause neuronal degeneration; (b) an immune response by cyto- 
toxic T cells against HTLV-I-infected neuronal cells or anti- 
body-dependent cellular cytotoxicity which induces destruc- 
tion of neuronal cells; (c) demyelination caused by cytokines 
secreted from HTLV-I-infected microglial cells; and (d) the 
activation of T  cells reactive to a neuronal self-antigen as a 
result of HTLV-I infection. 
The  aim  of this  study was to  clarify the pathogenesis 
of HAM/TSP,  therefore we focused on the localization of 
HTLV-I proviral DNA in the spinal cord lesions of HAM/TSP 
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immune mechanism is involved in the pathogenesis of HAM/ 
TSP, we analyzed the TCR V~ sequence of lymphocytes that 
infiltrated spinal cord lesions. 
Materials and Methods 
Patients and Control Samples.  Frozen spinal cord tissues and 
paraffin-embedded samples were obtained within 24 h of post- 
mortem intervals from autopsy cases with typical HAM/TSP cases 
(case 1, 74-yr-old female; case 2, 63-yr-old male; and case 3, 57-yr- 
old female), and ATL patient (39-yr-old male) and nonneurolog- 
ical disease controls (71-yr-old male and 88-yr-old female). PBLs 
were taken from healthy HTLV-I carriers (58-yr-old male and 59- 
yr-old female). 
Two-step PCR In Situ Hybridization.  Human brains and spinal 
cords of the three cases with HAM/TSP and one case with ATL 
and two normal subjects were fixed with neutralized 10% formalin 
solution for 2 wk. The samples were embedded in paraffin and 
cut into 5-/zm-thick sections. The sections were incubated at 65~ 
for I h and then deparaffinized  with xylene. After treatment with 
proteinase K (10 mg/ml) for 12 min at 37~  100 #1 of reaction 
mixture with 1 U of DNA Taq polymerase (Perkin Elmer-Cetus, 
Norwalk, CT), 10/zl of 10x reaction  buffer, 200 #M each ofdeoxy- 
nucleotide triphosphates, and 50 nM of each pX primer (5' primer, 
5'-ATAGCAAACCGTCAAGCACAGC-3'; 3'  primer, 5'-GAG- 
CCG TAACGCGTCCATCG-3')  was added to the slide  glass  which 
was then covered with a cover glass. The first PCR profile used 
began with denaturation at 94~  for 60 s, annealing at 37~  for 
7 min, and extension at 72~  for 90 s for 20 cycles, followed by 
a second  PCR profile  with denaturation at 94~  for 60 s, annealing 
at 55~  for 2 rain, and extension at 72~  for 90 s for 20 cycles 
on a flat-type DNA thermal cycler (model PHC-3; Techne, Ltd., 
Cambridge, UK). The reaction was terminated at 20~  Internal 
pX  probe (5'-CGGATACCCAGTCTACGT-3') was  tailed with 
biotin-dUTP by terminal deoxynucleotidyl transferase. In situ hy- 
bridization was done by utilizing the In Situ Hybridization and 
Detection System (BILL Life  Technologies, Bethesda, MD). Sec- 
tions  were examined with a Zeiss Axiophot  photomicroscope 
equipped with Nomarski optics. For a positive control, ~/globin 
primers (5'-ACACAACTGTGTTCACTAGC-Y  and 5'-GGAAAA- 
TAGGACCAATAGGCAG-3'; internal  probe 5'-GAAGTTGGT- 
GGTGAGGCCCT-Y) were used to show the sensitivity of this 
method. Immunoperoxidase staining of the consecutive sections 
was performed to identify T and B cells and macrophages with 
mAbs for T cell (MT-1, Bio-Science, Emmenbr/icke, Switzerland 
[5]; and UCHL-1, Dakopatts,  Copenhagen,  Denmark),  B cell 
(MB-2; Bio-Science, Emmenbr/icke, Switzerland),  macrophage 
(HLA-DR,  Dakopatts),  and microglia markers (polyclonal anti- 
body against ferritin; Dakopatts), respectively.  The colored reac- 
tion product was developed with diaminobenzidine. 
PCR.  Total  RNA was extracted from the thoracic spinal cord 
tissue of autopsy cases and PBLs from healthy HTLV-I  carrier using 
the  guanidine-phenol method (6). mRNA was purified using 
Oligotex-dT30. First-strand cDNA was made using 2 #g mRNA 
by Moloney-murine  leukemia  virus reverse transcriptase (BRL), then 
the cDNA  was  amplified with 20  VB-specific oligonucleotide 
primers  (Vfll,  5'-AAGAGAGAGCAAAAGGAAACATTCTTG- 
AAC-3'; V/~/2, 5'-GCTCCAAGGCCACATACGAGCAAGGCG- 
TCG-3';  V/33, 5'-AAAATGAAAGAAAAAGGAGATATTCCT- 
GAG-Y;  VB4,  5'-CTGAGGCCACATATGAGAGTGGGATTT 
GTCA-Y; V/~/5, 5'-CAGAGAAACAAAGGAAACTTCCCTGGT- 
CGA-Y; V/%, 5'-GGGTGCGGCAGATGACTCAGGGCTGCC- 
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CAA-3';  V/~7, 5'-ATAAATGAAAGTGTGCCAAGTCGCTTC- 
TCA-3';  V/~8, 5'-AACGTTCCGATAGATGATTCAGGGATG- 
CCC-3';  V/~9, 5'-CATTATAAATGAAACAGTTCCAAATCG- 
CTT-3';  V~I0,  5'-CTTATTCAGAAAGCAGAAATAATCAAT- 
GAG-3'; V~11, 5'-TCCACAGAGAAGGGAGATCTTTCCTCT- 
GAG-Y; V~12, 5'-GATACTGACAAAGGAGAAGTCTCAGAT- 
GGC-3'; V/813, 5'-ATGGCTACAATGTCTCCAGAT-3';  V/~14, 5'- 
GTGACTGATAAGC~AGATGTCCTGAACW_~-3';  V/815, 5'-GAT- 
ATAAACAAAGGAGAGATCTCTGATGGA-Y; V~16, 5'-CAT- 
GATAATCTTTATCGACGTGTTATGGGA-3'; V~17,  5'-TTT- 
CAGAAAGGAGATATAGTGAAGC~TAC-3';  V/~/18, 5'-GATGAG- 
TCAGAATGCCAAAGGAACGATTT-3'; V/~19, 5'-CAAGAA- 
ACGGAGATGCACAAGAAGCGATTC-Y;  V~20, 5'-ACCGAC- 
AGGCTGCAGGCAGGGGCCTCCAGC-Y) and C/~ primer (5'- 
GGCAGACAGGACCCCTTGCTGGTAGGACAC-Y)  (7). PCR 
samples were run in a 2% agarose gel and transferred onto nylon 
membrane (Zeta-probe; Bio-Rad  Laboratories,  Richmond, CA) after 
denaturation  with 0.4 N NaOH. Filters  were fixed  under UV lights, 
then prehybridized for 3 h at 42~  in 5x  SSPE/5x  Denhardt's 
solution/0.1%  SDS containing salmon sperm DNA (100/~g/ml) 
and hybridized overnight at 42~  with 106 cpm per ml of 32p-ki- 
nased internal C/8 probe (5'-TTCTGATGGCTCAAACACAGC- 
GACCTCGGG-3') as described (7). Actin PCR was done as previ- 
ously described (8). Filters were washed in 2 x SSC/0.1% SDS and 
0.5 x SSC/0.1% SDS each at room temperature, twice for 20 min, 
and then in 0.1x SSC/0.1% SDS at 42~  twice for 20 min. Kodak 
XAR-5 film with intensity screens were used for autoradiography 
at  -70~  for 5 h. 
Cloning and Sequencing.  After amplification  of the cDNA with 
V/3 specific  primers, a positive VB sample was independently run 
in a 2% Nusieve agarose gel and an appropriately sized fraction 
was excised from the gel, then cloned into pCR II vector (In- 
vitrogen, San Diego, CA). After transformation, clones  containing 
TCR/3 chain inserts were identified by colony hybridization with 
radiolabeled internal C~ probe as described  above. Double-stranded 
plasmid DNA from positive  clones  were prepared by alkaline  method 
and VB-Dfl-Jfl-Cfl  sequences were determined by the deoxy chain 
termination method using the Taq Dye Deoxy Terminator cycle 
sequencing kit (Applied Biosystems, Inc., Foster City, CA). 
Results 
Distribution of HTLV-I  Proviral DNA  in Spinal  Cord Le- 
sions.  A sensitive method we developed,  two-step PCR in 
situ hybridization which could detect as low as two copies 
of target DNA per cell (Fig.  l f,/3 globin control), was ap- 
plied to detect the HTLV-I proviral DNA in the spinal cord 
tissue sections of three autopsy cases plus other disease con- 
trols including central nervous system (CNS) ATL. Fig.  1 
shows the localization of HTLV-I proviral DNA in the spinal 
cord of HAM/TSP cases. HTLV-I proviral DNA was detected 
in the small round nucleus of lymphocyte-like cells which 
gathered mainly around the small blood vessels in the white 
matter (Fig.  1 a) as well as in the gray matter (Fig.  1 b) of 
the spinal cords. By morphological criteria, most of the HTLV- 
I-positive cells in the spinal  cords appeared  not to be glial 
cells, but rather lymphocytes. Immunohistochemistry anal- 
ysis using the T cell markers, MT-1 (pan-T) and UCHL-1 
(CD45RO) revealed a massive infiltration of T cells into the 
spinal cord (Fig.  I g). We found that the distribution of the 
the Central Nervous System of HAM/TSP HTLV-I proviral DNA-positive cells was almost identical to 
that of T lymphocytes in the serial sections  when we counted 
the proportion  of the HTLV-I proviral DNA-positive lym- 
phocytes. Most of the infiltrated lymphocytes were positive 
for the T  cell marker (Fig.  1 g) and were negative  for the 
B cell and macrophage markers. 50-70%  of the these lym- 
phocytes were positive  for HTLV-I  proviral DNA (Fig.  1, 
a and b). Numerous HTLV-I-positive  lymphocytes were also 
Table  1.  Vfl CDR3 Sequences of TCR Amplified from the Infiltrated Lymphocytes in Spinal Cords of HAM/TSP 
and Controls, and Vfl CDR3 Sequences of PBLs from HTLV-1 Healthy Carriers 
Number/ 
V/3  N-D-N  J~  CB  total* 
HAM/TSP Case  1 
V3  5  LCASS  LSGGAFD 
V/~  5  FCA  IGVR 
V/3  5  LCASS  LAPSGI~T 
V/3  5  LCASS  PGPGWGRW 
V/3  6  LCASS  LMGGG 
V/3  6  LCASS  PTGDY 
V/~  7  LCASS  ~D_PAAA 
V~  7  LCASS  QGTSY 
V/3  8  LCASS  LMGGG 
V/3  8  LCASS  LTGGSD 
V/3  12  FCA  IGVR 
V/~  12  FCASS  SGVSTDT 
V/3  13  LCASS  LSGGAFD 
V/~  13  FCASS  RNPDSS 
V~  14  FCAA  GRPVM 
HAM/TSP Case 2 
V/3  6  LCASS  PTGG 
V/3  6  LCASS  PTSPDGG 
V/3  8  LCASS  PEGN 
V/3  8  FCASS  R.HPDSS 
V/3  8  LCASS  WTGGGDT 
V/3  17  LCASS  GRLFS 
V/~  19  LCASS  PTRDYT 
V13  19  LCASS  QDGAAY 
Control  1 
V/3  7  FCASS  YRTGVKN 
VB  8  FCASS  FSRRQ 
V/~  12  FCASS  EDLRGY 
Control 2 
V/3  12  FCASS  PQGQLWQ 
Carrier PBL 
VB  2  FYICS  PVPLRGGDY 
V/5  6  LCASS  KQGE 
V/3  7  FCASS  R.NADT 
V/3  12  FCASS  YVGRGGY 
V/3  12  FCAIS  ESDSG 
VB  17  LCASS  NSGTSRQD 
EQYFGPGTRLTVT(JB2.7) 
EAFFGQGTRLTVV(J/~I. 1) 
QYFGPGTRLTVL(J/32.5) 
YTFGSGTRLTVV(J/~I.2) 
GYTFGSGTRLTVV(J/31.2) 
GYTFGSGTRLTVV(J/~I.2) 
YNEQFFGPGTRLTVL(J/32.1) 
YNEQFFGPGTRLTVL0/~2.1) 
GYTFGSGTR.LTVV(J/~I.2) 
GYTFGSGTRLTVV(J/~I.2) 
EAFFGQGTRLTVV(JB1.1) 
QYFGPGTR.LTVL(JB2.3) 
EQYFGPGTRLTVT0/~2.7) 
YNEQFFGPGTRLTVL(JB2.1) 
GYTFGSGTRLTVV(J/31.2) 
EQFFGPGTRLTVL(J/~2.1) 
EQYFGPGTRLTVL(J/32.7) 
EQFFGPGTRLTVL(J/~2.1) 
YNEQFFGPGTRLTVL(J/32.1) 
QYFGPGTRLTVL(J/32.3) 
NQPQHFGDGTRLSIL(J/31.S) 
YNEQFFGPGTRLTVL(J/32.1) 
GYTFGSGTRLTVV(J/31.2) 
TEAFFGQGTRLTVVIJ/51.1) 
NSPLHFGNGTRLTVT(J/31.6) 
GYTFGSGTR.LTVV(JIS1.2) 
ETQYFGPGTRLLVL(J/32.5) 
GYTFGSGTRLTVV(JB1.2) 
ETQYFGPGTRLLVL(JB2.5) 
QYFGPGTRLTVL(J/32.3) 
TEAFFGQGTRLTVV(JB1.1) 
NQPQHFGDGTRLSIL(JB  1.5) 
TQYFGPGTRLTVL(JI32.3) 
EDLKN  ......  2/5 
EDLNK  ....  .  .  1/5 
EDLKN  ......  1/5 
EDLNK  ......  1/5 
EDLNK  ......  2/4 
EDLNK  ......  1/4 
EDLKN  ......  1/3 
EDLKN  ......  2/3 
EDLNK  ......  2/5 
EDLNK  .......  2/5 
EDLNK  ......  1/3 
EDLKN  ......  2/3 
EDLKN  ......  3/5 
EDLKN  ......  2/5 
EDLNK  ......  2/2 
EDLKN  ......  3/5 
EDLKN  ......  1/5 
EDLKN  ......  1/3 
EDLKN  ......  1/3 
EDLKN  ......  1/3 
EDLNK  ......  5/5 
EDLKN  ......  2/4 
EDLNK  ......  1/4 
EDLNK  ......  2/2 
EDLNK  ......  2/2 
EDLNK  ......  1/1 
EDLKN  ......  5/5 
EDLNK  ......  3/3 
EDLKN  ......  4/4 
EDLKN  ......  2/3 
EDLNK  ......  1/3 
EDLNK  ......  2/3 
EDLNK  ......  3/4 
* The number of indicated CDP.3 sequences derived from bacterial colonies containing PCR-amplified DNA per total number of colonies sequenced. 
These sequence data are available from EMBL/GenBank/DDBJ  under accession numbers D31825-D31832  and D32014-D32038. 
833  Hara et al. Figure  1.  Distribution  of 
HTLV-I  proviral  DNA in the spinal 
cord lesions of three HAM/TSP au- 
topsy cases. HTLV-I  was detected  in 
the lymphocytes around the blood 
vessels in (a) white matter (HAM/ 
TSP case 2)  and  (b) gray matter 
of the  thoracic cord  (HAM/TSP 
case 1),  however, (c)  not  in  the 
motor neurons (HAM/TSP case 1) 
(arrows).  (d) HTLV-I-positive lym- 
phocytes were  also found  in  the 
thickened  leptomeninges  of  the 
spinal cord (HAM/TSP case 3). (e) 
All of the infiltrated  lymphocytes  in 
the medulla oblongata  ATL autopsy 
case  were  positive  for  HTLV-I 
proviral  DNA. (]) All nuclei of  cells 
in the spinal cord tissue were posi- 
tive for control/~  globin.  (g) Im- 
munostaining with T cell marker. 
All of the infiltrated lymphocytes  in 
the spinal cord of HAM/TSP case 
1 were positive for T cell marker, 
MT-1 (pan-T) (5). They were also 
positive for UCHI.d (CD45RO), 
and negative  for B cell  marker (MB- 
2) and macrophage marker (HLA- 
DR). (h) Activated microglia were 
positive for ferritin and negative for 
HTLV-I (HAM/TSP case 2). 
found in the thickened leptomeninges of the spinal cord (Fig. 
1 d). These findings contrasted the fact that most T  lympho- 
cytes that penetrated into the CNS of ATL patients contained 
the HTLV-I proviral DNA  in the nucleus (Fig.  1 e). On the 
other hand,  no HTLV-I proviral DNA  was detected in neu- 
ronal cells including motor neurons, astrocytes, oligodendro- 
cytes, and microglia of the spinal cord in any of the HAM/TSP 
cases (Fig.  1,  c and h).  Likewise,  nothing  was found in the 
sections  of the  non-HTLV-I carriers. 
Analysis of the TCR  Vfl CDR3 Sequence of the Infiltrated 
Lymphocytes.  To investigate the possibility of an autoimmune 
mechanism in the pathogenesis of HAM/TSP,  we analyzed 
TCR  V3  usage of lymphocytes that infiltrated  the  sites of 
inflammation in the spinal cords from the same two HAM/TSP 
834  Restricted V3 CDR3 Motifs in the Central Nervous System of HAM/TSP autopsy cases. Rearranged V/J 5, 6, 7, 8, 12, 13, and 14 genes 
in case 1 and V/J 6, 8,  17, and 19 genes in case 2 were each 
identified by PCR (Fig. 2).  Weak signals were observed in 
V/J  4,  11,  in case  1 and V/J  5,  10,  12,  13,  and  14  in case 
2; these V/J-expressed lymphocytes were a minor population, 
because the signal intensity was quantitatively less as com- 
pared with the actin control bands. We also sequenced these 
V/J transcripts to study V/J-D/J-J/J rearrangements (Table 1). 
Several clones from each V/J family were picked up and se- 
quenced.  Although the CDI~3  amino acid sequences were 
Figure 2.  Southern  blot analysis 
of TCR VB  repertoire. Samples 
were taken  from thoracic  spinal  cord 
of two patients with HAM/TSP 
case I and case 2. V/3-CB amplified 
products from spinal cord cDNA 
were analyzed  by Southern  blot hy- 
bridization using CB probe. Actin 
was amplified  in all V/3 samples as 
a  positive control  for  successful 
amplification of cDNA. 
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v~s 
SSLSGGAFD 
AGCAGCTTATCAGGGGGCGC~TTCGAC(J~2.7) 
SSLMGGG 
V~6  AGCAGCTT~TGGGGGGTGGT(J~I.2) 
v~  ~  ~I 
SSLMGGG 
V~8  AGCAGCTT~TGGGGGGCGGT(J~I.2) 
v~  ~ ~.  1 
SSLTGGSD 
V~8  AGCAGCTT~CAGGGGGTTCGGAT(J~I.2) 
v~  ~  n~.l 
SSLSGGAFD 
V~I3  AGCAGTTTATCAGGGGGCGCTTTTGAC(J~2.7) 
B 
v[36 
S  S  P  T  G  D  Y 
AGCAGCCCGACAGGGGACTAT  (J~l.  2  ) 
v~  N  D~1.1  N 
S  S  P  T  G  G 
V~6  AGCAOCCCGACAGGGGGT  (J~2.1) 
v~  N  n~1.1  N 
S  S  P  T  S  P  D  G  G 
v~6  AGCAGCCCGACTAGCCCCGATGCGGGA(J~2.7) 
v~  N  r)~2.1  N 
Figure 3.  VB'D3-J3 junctional nucleotide sequences of lymphocytes 
infiltrated in the spinal cord lesions of HAM/TSP patients. Genomic se- 
quences of each V3 and D3 are underlined.  These  sequence  data are available 
from EMBL/GenBank/DDBJ  under accession  numbers  D31825-D31832. 
identical in V36 and V38 or in V35 and V313 for case 1, 
the nucleotide sequences of the 5' V3 and CDR3 region of 
each V3 gene were different from one another (Fig. 3). One 
of the conserved motifs found in the spinal cord of HAM/TSP 
case 1 contained the sequence CASSLXG(G) (X is any amino 
acid) in the CDR3 region from V3 5,  6,  8,  and 13 tran- 
scripts. The number of colonies that showed the identical 
CDR3 sequence  per total colonies sequenced  in each V3 family 
is listed in Tables 1 and 2. The CDR3 LCASSLXG is similar 
to the CDR3 sequence found in the brain lesions of MS (9) 
and in a T cell clone recognizing myelin basic protein (MBP) 
peptide 87-106 from a MS patient (10) and in a rat T  cell 
clone recognizing MBP peptides 85-99 and 87-99 (11) (Table 
2). Other motifs found in the spinal cord of HAM/TSP cases 
have the sequence V36, V319CASSPT(G),  V37, V39CAS- 
SQD(G), and V317CASSGRL.  The CDR3 sequence CAS- 
SPT(G) also has been seen in brain lesions of MS (9) and 
CASSQD(G) was described in (PL/J  x  SJL)F1 T cell clone 
specific for rat MBP (12). CASSGRL was observed in a rat 
T cell clone recognizing MBP peptides 85-99 and 87-99 (10). 
None of these CDP,3 sequences was seen in the V3 sequence 
from the spinal cord tissues of disease control samples (total 
of 10 colonies sequenced) or peripheral blood T cells of healthy 
HTLV-I  carriers (total  of 20 colonies sequenced). 
Discussion 
Postmortem study of HAM/TSP cases revealed that there 
was demyelination and marked lymphocyte infiltration around 
small vessels  in the spinal cord, especially at the thoracic level 
(13). However, viral antigens have not been clearly identified 
in CNS tissue of HAM/TSP patients by immunohistochem- 
istry (14), mainly because the copy number of HTLV-I DNA 
is too low to detect.  A  sensitive method, as mentioned in 
Materials and Methods,  a two-step  PCR in situ hybridiza- 
tion (Morita,  M., H. Hachisuka,  and Y. Sasai, manuscript 
submitted for publication) has made it possible for us to de- 
tect the proviral DNA in paraffin-embedded spinal cord sec- 
tions. This method can detect as low as two copies of target 
DNA per cell. The present results show that HTLV-I proviral 
DNA was present only in the nuclei of infiltrated T lympho- 
cytes that gathered around small vessels in the spinal cord, 
but was absent in neuronal cells including neurons, glial cells, 
and microglial cells. Therefore, a slow viral infection of HTLV- 
I in neurons, an immunological response by cytotoxic T cells 
or antibodies against infected neuronal cells in the spinal cord 
tissue of HAM/TSP patients, is very unlikely. Although high 
frequency of cytotoxic CD8 + T cell specific  for HTLV-I pX 
was observed in HAM/TSP patients  (15), it is still hard to 
reason that this is the pathogenesis  of HAM/TSP because 
the existence of cytotoxic T cells for PX was also observed 
in healthy carriers of whom <1% developed the clinical dis- 
ease, and because  we could not find the HTLV-I proviral DNA 
in neuronal cells taken from the spinal cord of HAM/TSP 
autopsy cases. 
There are increasing reports that autoimmune-like condi- 
tions such as Sj6gren syndrome (16), Hashimoto disease (17), 
polymyositis (18), and uveitis (19) are often complicated in 
HAM/TSP patients. Several  phenomena of increased  immune 
response have been reported in HAM/TSP patients.  They 
have a high titer of anti-HTLV-I antibody in the serum and 
cerebro-spinal fluid, whereas ATL patients have a rather low 
titer. The number of activated, helper/inducer T cells is also 
increased in the peripheral circulation of HAM/TSP patients 
(20). It is known that these lymphocytes start to proliferate 
spontaneously  during in vitro culture (21). These findings 
led us to analyze TCR V3 sequence from the infiltrated lym- 
phocytes of HAM/TSP, because residues in CDR3 associated 
with a particular  V3 are critical for the whole affinity of a 
TCR for its ligand (22). Unique CDR3 sequences  were found 
in MBP-reactive T cell clones derived from EAE animals (10, 
12) and MS patients (11) as well as in the infiltrated lympho- 
cytes from the brain lesions of MS patients  (9). Wilson et 
al. (23) pointed out that an antigen recognition structure, 
which is composed of the particular sequence of the CDP,3 
junctional region in combination with a certain/9 chain vari- 
able region, may play a crucial role in the pathogenesis of 
EAE and MS. 
TCR V[3-Df3-J3 CDR3  sequences of lymphocytes that 
infiltrated into the spinal cords of HAM/TSP patients were 
highly conserved. These CDR3 motifs, CASSLXG(G), CAS- 
SPT(G), CASSQD(G), and CASSGRL, were similar to those 
found in the brain lesions of MS patients and in the T cell 
836  Restricted  Vfl CDR3 Motifs in the Central Nervous System of HAM/TSP Table  2.  Comparison  of Vl~ CDR3 Amino Acid Sequences among HAM/TSP, MS, and MBP-reactive T  Cell Clones 
HAM/TSP 
Case 1  V3 
V3 5  CASS 
V/~ 6  CASS 
V3 8  CASS 
v3 8  CASS 
V3  13  CASS 
MS brain lesions* 
V35.2  CASS 
vB5.2  CASS 
N-D-N 
LSGGAFD 
LMGGG 
LMGGG 
LTGGSD 
LSGGAFD 
LRGAN 
LGGSE 
T  cell clone for MBP pep 87-106 from MS patients 
V35.2  CASS  LR.GAL 
Lewis rat EAE T  cell clone for MBP peptides 
85-99 and 87-98ii 
V~8.2  CASS  LGGE 
v3 6  CASS  LRG 
HAM/TSP 
Case 1  V3  N-D-N 
v3 6  CASS  PTGDY 
Case 2 
V/3 6  CASS  PTGG 
V3 6  CASS  PTSPDGG 
V~ 17  CASS  GRLFS 
V3  19  CASS  PTRDYT 
MS brain lesions* 
V~ 5  CASS  PT 
Lewis rat EAE T cell clone for MBP peptides 
85-99 and 87-98  II 
VI3 4  CASS  GRLGE 
HAM/TSP 
Case 1  V3  N-D-N 
V3 7  CASS  Q_D_PAAA 
Case 2 
V3 19  CASS  QDGAAY 
(PL/J  x  SJL)Ft T  cell clone specific for rat MBPI 
V3 4  CASS  QDGWGNQ 
J3 
EQYFGPGTRLTVT(J32.7) 
GYTFGSGTRLTVV(J31.2) 
GYTFGSGTRLTVV(J/~I.2) 
GYTFGSGTRLTVV(J/31.2) 
EQYFGPGTRLTVT(J32.7) 
J3 2.6 
j3 2.5 
J3 2.4 
J3 2.5 
JB 1.6 
J3 
GYTFGSGTRLTVV(J31.2) 
EQFFGPGTRLTVLOB2.1  ) 
EQYFGPGTRLTVL (J/32.7) 
NQPQHFGD  GTRLSIL(J/~I.5) 
YNEQFFGPGTRLTVL(J/32.1) 
GANVLTFGAGSRLTVL(J32.6) 
YAEQ  ..........  (J/~2.1) 
Number/total* 
2/5 
2/4 
2/5 
2/5 
3/5 
Number/total* 
1/4 
3/5 
1/5 
5/5 
2/4 
JB  Number/total* 
YNEQFFGPGTRLTVL(JB2.1)  1/3 
GYTFGSGTRLTVV(J31.2) 
j32.5 
1/4 
* The number of indicated CDR3 sequences  derived  from bacterial colonies  containing PCR-amplified  DNA per total number of colonies sequenced. 
* Oksenberg et al. (9). 
S  Martin et al. (10). 
II Gold et al. (11). 
I Acha-Orbea et al. (12). 
clones with specificity for MBP as shown in Table 2.  One 
of such unique motifs, CASSLXGG, was  also  identical to 
a motif found in SJL/J mice T  cell clones which recognizes 
MBP peptides 89-101 (24). Although TTA codon for the Leu 
residue of CASS_LXGG motif is mostly encoded in germline 
V3  genes  (25-27),  these TTA nucleotides are frequently 
deleted for other nucleotides are randomly added, so that this 
Leu residue is not always conserved in the TCR V3-DBjunc- 
tion of the T  cell clones previously reported (9, 28). There 
is a possibility that GlyGly residues seen in the CASSLXG_G_G 
837  Hara et al. motif  are derived from germline D segments (27). However, 
we could not find this CASSLXG(G) motif in any of the 
CDK3 sequences obtained from both the control spinal cords 
and PBLs of healthy carriers.  Therefore, it appears that this 
unique motif, which is conserved in the TCR CDR3 region 
of MBP-reactive T  cell clones from MS and EAE patients 
(9,  10,  11,  23),  is  also  present  in  the  TCR  CDR3  of 
HAM/TSP infiltrated T  cells. The fact that T  cells bearing 
such a specific TCR CDR3 sequence are found in the spinal 
cord lesions  of HAM/TSP patients as well as in the brain 
lesions of MS patients raises some thought-provoking ques- 
tions on the etiology of these diseases. 
The TCK CDR3 motifs found in HAM/TSP patients, 
which are highly conserved even though they have different 
V3 families, may arise because of a genetically based, struc- 
turally determined preference for this particular VDJ recom- 
bination. Another possible explanation for the genesis of these 
conserved motifs may be that certain specific antigen-MHC 
complexes positively select for these unique CDR3 motifs. 
If the latter is true, self-antigens such as MBP,  proteolipid 
protein, and heat shock protein, which are frequently released 
and exposed to immune system during CNS inflammation, 
are primary candidates to be TCR ligands. 
Recently, Lunardi-Iskander, et al. (29) reported that HTLV-I 
infection was  associated  with abnormal proliferation and 
differentiation of T cell progenitors in vitro. Therefore, one 
hypothesis to explain the pathogenesis of HAM/TSP is that 
T cells reactive to self-antigens may exist in a state of anergy 
in the periphery. These self-reactive T cells become activated 
and propagate in some genetically predisposed individuals upon 
HTLV-I infection. Identification of the antigen(s) that is rec- 
ognized by T cell clones bearing these unique TCR V3 CDR3 
sequences  from HAM/TSP patients is now under investi- 
gation. 
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